Pioneer in Biphasic Calcium Phosphate Solutions, especially in custom inserts for spinal cages, Biomatlante has been the Partner of choice of major spinal companies worldwide for over 20 years.
- Ready to use cage filler
- Operating time saved with prefilled cages
- Cost effective and safe
MBCP™ Technology’s Key Features
Provides a matrix for new bone growth
HA alone resorbs too slowly while TCP resorbs too fast. Bi-phasic HA and TCP allow for a resorption rate similar to that of human bone.
Interconnected network of macropores and micropores that enables the colonization of bone cells and biological fluid uniformly within the matrix.
For ionic exchange: TCP dissolution and bone crystal precipitation. Newly bioactive interface with bone cells.
Macropores are a network of interconnected spaces that promote the biological infiltration and cellular colonization by osteoblasts and osteoclasts.
Micropores are the intercrystalline spaces where dissolution and recrystallisation occurs.
Host bone formation is systematically demonstrated.
100% synthetic – 5 years shelf life.
The effectiveness of MBCP™ has been critically evaluated in a large prospective randomized study involving 341 patients undergoing posterior spinal fusion with associated instrumentation³. The performance of MBCP™ was characterized by:
- Equivalent clinical outcome to autologous bone graft
- Fewer spinal wound healing problems than autologous grafts
- Avoidance of donor site pain and infections
- No allergic reactions
2. Daculsi G.,Jegoux F. and Layrolle P. «The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering», Advanced Biomaterials: Fundamentals, Processing, and Application, B. Basu. et al., J. Wiley and sons Inc., pp101-141 (2009)
3. Ransford A.O. and al., “Synthetic porous ceramic compared with autograft in scoliosis surgery. A prospective, randomized study of 341 patients.” J Bone Joint Surg Br, 80(1): 13-8. (1998)
4. Gouin F., Delecrin J. , Passuti N., Touchais S., Poirier P., Bainvel J., “Biphasic macroporous calcium phosphate ceramic bone substitute for filling bone defects: A report of 23 cases.” Revue de Chirurgie Orthopedique: 81; 59–65 (1995)
5. Daculsi G. , Corlieu P. , Bagot D’Arc M., Gersdorff M., “Macroporous biphasic calcium phosphate efficiency in mastoid cavity obliteration: experimental and clinical findings.” Annals of Otology, Rhinology & Laryngology: 101(8); 669–674 (1992).
6. Daculsi G. , Passuti N., Martin S., Deudon C. , Legeros R., Raher S., “Macroporous calcium phosphate ceramic for long bone surgery in humans and dogs. Clinical and histological study.” Journal of Biomedical Materials Research: 24; 379–396 (1990).
MBCP™ must not be used for femoral or tibial osteotomies without appropriate opening osteotomy system devices, plates and screws.
Maximum contact between the product and the recipient bone must be established.
The implantation in a revision surgical site containing non-resorbable fragments of material (e.g. polyethylene ligament waste, carbon fibers) is not recommended.
As with any surgical procedure, care should be exercised in treating individuals with preexisting conditions that may affect the success of the surgical procedure. This includes (but is not limited to) individuals with long-term steroidal therapy or treatment acting on the calcium or phosphorus metabolism.
MBCP™ is radiopaque until resorbed. Radiopacity may mask underlying pathological conditions. Radiopacity may also make it difficult to radiographically assess the ingrowth of new bone.
MBCP™ is intended for use by surgeons familiar with bone grafting and rigid fixation techniques.
MBCP™ has not been tested on pregnant women. The risk of health has not been established.
- ISO 13485
- Read the instructions for use
- MBCP™ is supplied sterile and CE-marked as a Class III Medical Device according to Directive EEC/93/42
- Interbody Cage Fusion
MBCP™ Inserts are available in: